Worldwide antimicrobial susceptibility patterns and pharmacodynamic comparisons of gatifloxacin and levofloxacin against Streptococcus pneumoniae: Report from the antimicrobial resistance rate epidemiology study team

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 1, 2003, Pages 292-296

  Jones, Ronald N ^a   Rubino, Christopher M ^a   Bhavnani, Sujata M ^a   Ambrose, Paul G ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

GATIFLOXACIN; LEVOFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIUM ISOLATE; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; NONHUMAN; PRIORITY JOURNAL; PROBABILITY; RESPIRATORY TRACT INFECTION; STATISTICAL ANALYSIS; STATISTICS; STREPTOCOCCUS PNEUMONIAE;

EID: 0037229596     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.1.292-296.2003     Document Type: Article

References (19)

1. Ambrose, P. G., R. C. Owens, and D. M. Grasela. 2000. Antimicrobial pharmacodynamics. Med. Clin. N. Am. 84:1431-1446.
2. Ambrose, P. G., and D. M. Grasela. 2000. The use of Monte Carlo simulation to examine the pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae. Diagn. Microbiol. Infect. Dis. 38:151-157.
3. Ambrose, P. G., D. M. Grasela, T. H. Grasela, J. Passarell, H. B. Mayer, and P. F. Pierce. 2001. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob. Agents Chemother. 45:2793-2797.
4. Chen, D. K., A. McGeer, J. C. de Azavedo, and D. E. Low. 1999. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N. Engl. J. Med. 341:233-239.
5. Craig, W. A. 2001. Pharmacodynamics of antimicrobials: general concepts and application, p. 1-22. In C. H. Nightingale, T. Murakawa, and P. G. Ambrose (ed.), Antimicrobial pharmacodynamics in theory and clinical practice. Marcel-Dekker, Inc., New York, N.Y.
6. Davies, T. A., G. A. Pankuch, B. E. Dewasse, M. R. Jacobs, and P. C. Applebaum 1999. In vitro resistance of five quinolones and amoxicillin-clavulanate in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 43:1177-1182.
7. Drusano, G. L., S. L. Preston, C. Hardalo, R. Hare, C. Banfield, D. Andes, O. Vesga, and W. A. Craig. 2001. Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint. Antimicrob. Agents Chemother. 45:13-22.
8. Drusano, G. L., D. E. Johnson, M. Rosen, and H. C. Standiford. 1993. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob. Agents Chemother. 37:483-490.
9. Dudley, M. N., and D. Griffith. 2001. Animal models of infection for the study of antibiotic pharmacodynamics, p. 67-97. In C. H. Nightingale, T. Murakawa, and P. G. Ambrose (ed.), Antimicrobial pharmacodynamics in theory and clinical practice. Marcel Dekker, Inc., New York, N.Y.
10. Dudley, M. N., and P. G. Ambrose. 2000. Pharmacodynamics in the study of resistance and establishing in vitro susceptibility breakpoints: ready for prime time. Curr. Opin. Microbiol. 3:515-521.
11. Hoban, D. J., G. V. Doern, A. C. Fluit, M. Roussel-Delvallez, and R. N. Jones. 2001. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveilance Program, 1997-1999. Clin. Infect. Dis. 32(Suppl. 2):S81-S93.
12. Jones, R. N., and M. A. Pfaller. 2000. In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance: data from the SENTRY Antimicrobial Surveillance Program. Clin. Infect. Dis. 31(Suppl. 2): S16-S23.
13. Jones, R. N., and M. A. Pfaller. 2000. Macrolide and fluoroquinolone (levofloxacin) resistances among Streptococcus pneumoniae strains: significant trends from the SENTRY Antimicrobial Surveillance Program (North America, 1997-1999). J. Clin. Microbiol. 38:4298-4299.
14. Lacy, M. A., W. Lu, X. Xu, P. R. Tessier, D. P. Nicolau, R. Quintiliani, and C. H. Nightingale. 1999. Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection. Antimicrob. Agents Chemother. 43:672-677.
15. Lister, P. D., and C. C. Sanders 1999. Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae. J. Antimicrob Chemother. 43:79-86.
16. National Committee for Clinical Laboratory Standards. 2000. Performance standards for antimicrobial susceptibility testing. Document M7-A5. National Committee for Clinical Laboratory Standards, Wayne, Pa.
17. National Committee for Clinical Laboratory Standards. 2001. Performance standards for antimicrobial susceptibility testing. Document M100-S11. National Committee for Clinical Laboratory Standards, Wayne, Pa.
18. Preston, S. L., G. L. Drusano, A. L. Berman, C. L. Fowler, A. T. Chow, and B. Dornseif. 1998. Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection. Antimicrob. Agents Chemother. 42:1098-1104.
19. Weiss, K., C. Resteri, R. Gauthier, M. Laverdiere, A. McGeer, R. J. Davidson, L. Kilburn, D. J. Bast, J. de Azavedo, and D. E. Low. 2001. A nosocomial outbreak of fluoroquinolone-resistant Streptococcus pneumoniae. Clin. Infect. Dis. 33:517-522.